Navigation Links
Neurobiological Technologies Appoints Matthew M. Loar as Chief Financial Officer
Date:4/1/2008

EMERYVILLE, Calif., April 1, 2008 /PRNewswire-FirstCall/ -- Neurobiological Technologies, Inc. (NTI(R)) (Nasdaq: NTII), today announced that, effective April 1, 2008, Matthew M. Loar has been appointed Chief Financial Officer. Mr. Loar will be based at the Company's headquarters in Emeryville. Mr. Loar joins the company from Osteologix, where he has served as Chief Financial Officer since 2006.

"Matt has a proven track record as a chief financial officer, and we will look to his expertise to help guide our financial and business strategy," said Paul E. Freiman, President and Chief Executive Officer of Neurobiological Technologies. "His wealth of experience in helping to run several businesses combined with his knowledge of industry accounting requirements, SEC compliance and the biotech investment community will be real assets as our team continues to advance our strategic vision."

Mr. Loar is a Certified Public Accountant and has over twenty years experience in finance and accounting. Mr. Loar has a strong track record working with growing pharmaceutical and biotechnology companies, and has played a key role in several major corporate collaborations, successfully completing public and private equity financings and implementing the provisions of Sarbanes-Oxley Act at a public biotechnology company.

"NTI has a strong management team, a unique product development strategy, and tremendous potential for their phase 3 investigational drug, Viprinex(TM).

I look forward to becoming a key contributor to their future growth," said Mr. Loar. "NTI's efforts to develop new and improved central nervous system therapeutics are indeed exciting, and I'm anxious to start working with the other members of NTI's team to maximize the organization's overall potential."

Since the fall of 2006, Mr. Loar held the position of Chief Financial Officer at Osteologix, Inc. Prior to his tenure at Osteologix, he spent eleven years with Genelabs Technologies, Inc. where he held several positions, including Chief Financial Officer, Vice President of Finance and Controller. Earlier in his career, from 1991 through 1995, Mr. Loar was Corporate Accounting Manager for an international manufacturing company with approximately $500 million in annual product sales. From 1986 to 1991 he was audit manager with Coopers & Lybrand, a predecessor firm to PriceWaterhouseCoopers. Mr. Loar graduated from the University of California, Berkeley and is a member of the American Institute of CPAs. He is a member of Financial Executives International and for two years served as treasurer of their Silicon Valley Chapter.

As an inducement to his entering into employment with the Company, Mr. Loar was awarded an option in accordance with NASDAQ Marketplace Rule 4350(i)(1)(A)(iv) to purchase up to 150,000 shares of the Company's common stock outside of the Company's stockholder-approved equity incentive plans, at an exercise price per share equal to the fair market value of the Company's common stock on April 1, 2008. The inducement option, which will have a term of 10 years, will vest with respect to one-eighth of the underlying shares six months after the date of grant and then with respect to the remaining shares ratably over the next 42 months.

About Neurobiological Technologies

Neurobiological Technologies, Inc, (Nasdaq: NTII) is a biopharmaceutical company focused on developing novel, first-in-class agents for central nervous system conditions and other serious unmet medical needs. The Company's most advanced product candidate in phase 3 clinical testing is Viprinex(TM) (ancrod), a novel agent with multiple mechanisms that is specifically designed to expand the treatment window for treating acute ischemic stroke, one of the most prevalent, debilitating and costly diseases in the world for which there are few acceptable treatment options. Its pipeline includes other drug candidates in early-stage development, including a first-of-its-kind drug for the treatment of Alzheimer's disease.


'/>"/>
SOURCE Neurobiological Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Neurobiological Technologies, Inc. Reports Receipt of Notice From Nasdaq
2. Neurobiological Technologies, Inc. Reports Fourth Quarter and Fiscal Year-End Financial Results for 2007 Announces 1-for-7 Reverse Stock Split
3. Neurobiological Technologies, Inc. (Nasdaq: NTIID)
4. Neurobiological Technologies Announces Pricing of Its $60 Million Common Stock Offering
5. Neurobiological Technologies, Inc. (Nasdaq: NTII) Q1/08 Review Issued By Scimitar Equity Research, Inc.
6. Neurobiological Technologies, Inc. Reports Retirement of Ronald E. Cape, Ph.D., from Board
7. Neurobiological Technologies Sets Date for Second Quarter Financial Results
8. Update: Neurobiological Technologies Sets Date for Second Quarter Financial Results and Conference Call
9. Neurobiological Technologies, Inc. (Nasdaq: NTII) Q2/08 Review Issued By Scimitar Equity Research, Inc.
10. Neurobiological Technologies Sets Date for Research and Development Day
11. Neurobiological Technologies Reports $2.1 Million Quarterly Payment for Sales of Memantine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... Biocom, the association representing the Southern California ... San Diego companies to Washington D.C. ... Fly-In. Biocom Fly-In participants had the opportunity to meet with ... for Medicare and Medicaid Services (CMS), the National Institutes of ... Susan Davis and Scott Peters to discuss ...
(Date:2/12/2016)... Feb. 12, 2016  BD (Becton, Dickinson and Company) ... company, today announced the launch of the BD CLiC™ ... Technology (AGBT) Meeting. --> ... research by providing cost effective NGS library preparation with ... high-throughput, fully integrated, next generation sequencing (NGS) library prep ...
(Date:2/12/2016)... SAN FRANCISCO , February 12, 2016 /PRNewswire/ ... Precision Medicine Efforts by Enabling Scientific Understanding of ... Disorders and Rare Diseases --> ... for genomic diagnostics in South Asia and a leading ... it would contribute $10 million to the GenomeAsia ...
(Date:2/11/2016)... Inc. (NASDAQ: NBIX ) today announced its financial results for ... --> --> For the fourth quarter of ... $0.34 loss per share, compared to a net loss of $19.4 ... 2014. For the year ended December 31, 2015, the Company reported ... as compared to a net loss of $60.5 million, or $0.81 ...
Breaking Biology Technology:
(Date:1/25/2016)... -- Glencoe Software, the world-leading supplier of image data management ... the data management solution OMERO Plus for the newly ... Photo - http://photos.prnewswire.com/prnh/20160125/325328LOGO ... Phenotypic analysis measures the characteristics and behavior of cells, ... such as health and disease, the presence or absence ...
(Date:1/22/2016)... 2016 http://www.researchandmarkets.com/research/p74whf/global_biometrics ... "Global Biometrics Market in Retail Sector ... --> http://www.researchandmarkets.com/research/p74whf/global_biometrics ) has announced ... Market in Retail Sector 2016-2020" report ... Research and Markets ( http://www.researchandmarkets.com/research/p74whf/global_biometrics ) has ...
(Date:1/20/2016)... -- A market that just keeps on growing. Molecular ... in genomics knowledge. Learn all about it in this ... dynamic trends are pushing market growth and company valuations. ... - pathogen evolution - next generation sequencing - emergence ... of the role of genetic material in Disease and ...
Breaking Biology News(10 mins):